newsfilter
← Latest News
GlobeNewswire·

Dianthus Therapeutics Highlights Recent Business Achievements, Including GO Decision for Phase 3 CAPTIVATE CIDP Trial, and Reports Q4 and FY 2025 Financial Results

Early GO decision reached in CAPTIVATE ahead of Q2'26 guidance based on GO criteria of 20 confirmed responders achieved with less than 40 planned participants completing open-label Part A Phase 3 registrational trial